IFF Tackles Top Challenges in Baking at IBIE 2025
2.9.2025 14:00:00 EEST | Business Wire | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, health and biosciences, will showcase how it is helping the global baking industry overcome some of its toughest challenges at the International Baking Industry Exposition (IBIE) 2025 in Las Vegas. From soaring cocoa and egg prices to stricter regulations and rising demand for healthier baked goods, IFF is stepping forward with bold, science-led solutions designed to keep industrial bakers ahead of the curve.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902465856/en/
“The industry is under pressure from every direction — supply chains, regulations and consumer expectations,” said Suzanne Pera, vice president and regional general manager for North America, IFF Food Ingredients. “Our message at IBIE is simple: Bakers don’t have to face these challenges alone. We bring unmatched expertise across the entire process, from formulation to shelf. We’re not just helping bakers adapt — we’re helping them win.”
Addressing the cost of volatility
With cocoa prices doubling and egg supplies remaining strained, IFF CURE™ — a comprehensive suite of Core and Uncommon Replacements and Extenders — offers solutions that maintain taste and texture while reducing reliance on volatile commodities. At the booth, visitors can sample 50 percent egg-reduced cupcakes and 30 percent cocoa-reduced brownies made with proprietary enzyme blends, system blends and natural flavors.
Navigating regulatory shifts
With certain food dyes now banned and the industry reevaluating what quantifies as “healthy,” bakers face increasing reformulation demands. IFF spotlights natural color alternatives, label-friendly hydrocolloids and shelf-life extension solutions that keep products compliant without sacrificing sensory appeal.
Meeting the health-conscious consumer
GLP-1 users are reshaping food and beverage demand, while shoppers broadly seek lower sugar, more protein and label-friendly bakery options. The prototypes reflect how IFF translates consumer and regulatory insights into market-ready products, featuring better-for-you concepts like high-protein tortillas and consumer-validated nutrition bars fortified with SOLAE® SUPRO® soy protein and LITESSE® ULTRA prebiotic fiber.
Breakthrough baking technologies debut
IFF will debut DANISCO® GRINDSTED® Pectin FB 420, a bake-stable pectin made from citrus peels. This naturally sourced, label-friendly alternative to starch enhances flavor release and mouthfeel, while delivering a bright, glossy texture in reduced-sugar bakery applications. Also launching is POWERFRESH® ACE 2000, a next-generation fresh-keeping enzyme that improves bread softness, resilience and cohesiveness for up to 34 days.
“We are not just displaying ingredients,” said Linda Dunning, applications director, North America, IFF Food Ingredients. “We are showing how real-world solutions can raise the game for bakers — ideas that work in the lab, are scalable in production and stand out on the shelf.”
Attendees will experience go-to-market applications, designed to inspire product innovations while solving some of the baking industry’s toughest challenges. IFF will be at IBIE 2025 from Sept. 14-17 at the Las Vegas Convention Center, booth 3855.
To learn more about IFF at IBIE and its bold, future-forward baking solutions, visit the IFF IBIE 2025 page here.
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.
©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250902465856/en/
Contacts
Jasmine Chia
Global Communications Director, Food Ingredients
+65 9827 3808
Jasmine.Chia@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom